Trial Profile

A study investigating rivaroxaban to assess various outcomes of cancer patients with blood clots who are treated with an anticoagulant to better understand the treatment of VTE and the prevention of recurrent events in this patient population

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 18 Dec 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Dec 2015 According to a Janssen Pharmaceuticals media release, results from first 200 patients were presented at the 2015 American Society of Hematology (ASH) Annual Meeting.
07 Dec 2015 Results from first 200 patients were published in a Janssen Pharmaceuticals media release.
07 Dec 2015 Status changed from planning to recruiting, according to a Janssen Pharmaceuticals media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com